文献速递小儿骨科骨质疏松与代谢性骨病创伤骨科

脊髓性肌萎缩症儿童静脉双膦酸盐治疗的安全性

Intravenous bisphosphonate therapy in children with spinal muscular atrophy.
PubMed 文献 · Osteoporos Int · 2019-12-02

本文首次报告静脉双膦酸盐(IV BP)治疗脊髓性肌萎缩症(SMA)儿童废用性骨质疏松和低骨密度的安全性与疗效。回顾性分析8例患者共39次输注,急性期反应在首次输注后占38%、后续输注后占3%,骨密度1年时有改善趋势,6例随访>2年者骨折率从1.4降至0.1次/年,但1例发生非典型股骨骨折。结论认为IV BP在SMA儿童中似乎安全且能降低骨折率,但需警惕非典型股骨骨折。

要点

  • IV BP在SMA儿童中急性副作用轻微,但需警惕非典型股骨骨折。
  • 6例随访>2年者骨折率从1.4降至0.1次/年。
  • 骨密度在治疗后1年呈改善趋势。

核心结论

  • 在SMA儿童中,IV BP治疗似乎安全且急性副作用轻微,并能降低骨折率。
  • 鉴于SMA人群中发生非典型股骨骨折,仍需谨慎。

研究设计与样本

  • 回顾性病历审查,纳入2010至2018年一家三级儿科中心接受IV BP治疗废用性骨质疏松和低骨密度的SMA儿童。
  • 共8例患者(50%女性;75%为SMA 1型;首次输注中位年龄6.7岁),总计39次输注(54%帕米膦酸,46%唑来膦酸)。

主要发现

  • 首次输注后急性期反应发生率为38%,后续输注后为3%。
  • 治疗后1年骨密度呈改善趋势。
  • 6例随访超过2年的患者中,骨折率从1.4次/年降至0.1次/年。
  • 1例患者观察到非典型股骨骨折。

临床怎么用

  • 对于SMA合并废用性骨质疏松和低骨密度的儿童,可考虑使用IV BP以降低骨折率。
  • 治疗期间应监测急性期反应,并警惕非典型股骨骨折的发生。

局限性

  • 回顾性研究,样本量小(8例),来自单一中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This is the first report on safety and efficacy of intravenous bisphosphonates (IV BP) for treatment of disuse osteoporosis and low bone mineral density (BMD) in children with spinal muscular atrophy (SMA). IV BP appears to be safe and effective in fracture rate reduction. However, caution is necessary given the occurrence of an atypical femur fracture. INTRODUCTION: Children with SMA are at high risk for fragility fractures and low BMD. IV BP have been used for treatment of disuse osteoporosis in pediatrics. However, safety and efficacy of IV BP in the SMA population has not been reported. METHODS: Retrospective chart review of IV BP for treatment of disuse osteoporosis and low BMD in children with SMA at a tertiary pediatric center from 2010 to 2018 RESULTS: Eight patients (50% female; 75% SMA type 1; median age at first infusion 6.7 years) receiving a total of 39 infusions (54% pamidronate, 46% zoledronic acid) were included in this report. Acute phase reactions occurred following 38% and 3% of initial and subsequent infusions, respectively. BMD trended toward improvement at 1 year post-treatment. Among six patients who had > 2 years of follow-up, fracture rate decreased from 1.4 to 0.1 fracture/year. An atypical femur fracture was observed in one patient. CONCLUSION: These findings suggest that in children with SMA, IV BP therapy appears to be safe with minimal acute side effects and effective to reduce fracture rate. Caution is still needed given the occurrence of an atypical femur fracture in SMA population.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nasomyont N, Hornung LN, Wasserman H, et al. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporos Int. 2019. PMID: 31788718. doi:10.1007/s00198-019-05227-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。